3-氨基-2-甲基-5-硝基苯甲酰胺 | 3572-44-9

• 物质功能分类: 分析化学 - 标准品 - 分析标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基-2-甲基-5-硝基苯甲酰胺
• 英文名称: 5-amino-3-nitro-o-toluamide
• 英文别名: 3-amino-5-nitro-o-toluamide；3-Amino-2-methyl-5-nitrobenzamide
• CAS: 3572-44-9
• 化学式: C₈H₉N₃O₃
• mdl: MFCD01679715
• 分子量: 195.178
• InChiKey: RBLRQBGOUCRKRT-UHFFFAOYSA-N

物化性质

• 熔点：
  198.5-199.5°
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  115
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2924299090

制备方法与用途

生物活性方面，3-ANOT 是二氯苯酮（Dinitolmide）的代谢物，而二氯苯酮是一种常用于家禽生产中的硝基酰胺类抗球虫药物。

反应信息

• 作为产物：
  描述：

  二硝托胺 在 palladium on activated charcoal 、 环己烯 作用下， 以 乙醇 为溶剂， 生成 5-氨基-2-甲基-3-硝基苯甲酰胺 、 3-氨基-2-甲基-5-硝基苯甲酰胺
  参考文献：
  名称：

  Chemical Reduction of Zoalene to ANOT for Use in Zoalene Residue Studies

  摘要：

  A novel chemical synthesis and purification scheme to produce ANOT (3-amino-5-nitro-o-toluamide) was developed to yield an analytical standard grade material for zoalene residue investigations. An original conversion of zoalene (3,5-dinitro-o-toluamide) to ANOT was developed. Several literature references were available for the partial reduction of dinitro aryl compounds, but none detailed the conversion of zoalene to ANOT. A chemical synthesis was chosen over a biological synthesis due to the latter's complex reaction matrix, difficult recovery, and low batch yields. Using general partial reduction of dinitro aryl schemes, it was found that 10% palladium on carbon coupled to a cyclohexene reducing agent provided an optimum ANOT yield. Chromatographic techniques were utilized to isolate ANOT from the product mixture and to purify it to a standard grade material (>99% pure). The chemically synthesized ANOT product was characterized using colorimetric, TLC, FTIR, NMR, and LC/MS techniques.

  DOI：

  10.1021/jf9802068

文献信息

• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：CENTAURUS BIOPHARMA CO LTD

  公开号：WO2014082598A1

  公开（公告）日：2014-06-05

  The invention provides novel poly-substituted 5-membered heterocyclic compounds represented by Formula (IV), or a pharmaceutically acceptable salt, solvate, metabolites, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as selective irreversible bruton's tyrosine kinase (Btk) inhibitors and is further useful to treat inflammatory, auto immune diseases associated with aberrant B-cell proliferation such as RA (rheumatoid arthritis) and cancers. This invention also provided the preparation of a medicament using of Formula (IV), and methods of preventing or treating diseases associated with excessive Btk activity in mammals, especially humans. Formula (IV)

  该发明提供了由化学式（IV）表示的新型多取代的5-成员杂环化合物，或其药学上可接受的盐、溶剂化合物、代谢物、多形体、酯、互变异构体或前药，以及包含这些化合物的组合物。所提供的化合物可用作选择性不可逆的布鲁顿酪氨酸激酶（Btk）抑制剂，并且进一步用于治疗与异常B细胞增殖相关的炎症、自身免疫疾病，如类风湿关节炎（RA）和癌症。该发明还提供了利用化学式（IV）制备药物的方法，以及预防或治疗与哺乳动物，尤其是人类中Btk活性过高相关的疾病的方法。 化学式（IV）
• [EN] COMPOUNDS, THEIR SYNTHESES, AND THEIR USES<br/>[FR] COMPOSÉS, LEUR SYNTHÈSE ET LEURS UTILISATIONS
  申请人：UNIV LOUISVILLE RES FOUND

  公开号：WO2010019861A1

  公开（公告）日：2010-02-18

  Embodiments of the present invention provide compounds (such as Formula (I) compounds, Formula (II) compounds, and various embodiments thereof). Compositions comprising those compounds are also provided. Methods for their preparation are included. Also, uses of the compounds are included, such as administering and treating diseases (e.g., cancer and infections).

  本发明实施例提供化合物（如式（I）化合物、式（II）化合物及其各种实施例）。还提供包含这些化合物的组合物。包括它们的制备方法。此外，还包括化合物的用途，如给药和治疗疾病（例如癌症和感染）。
• [EN] INHIBITORS OF AKT ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITE D'AKT
  申请人：MERCK & CO INC

  公开号：WO2005100356A1

  公开（公告）日：2005-10-27

  The present invention is directed to compounds which contain substituted napthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

  本发明涉及含有取代萘啶的化合物，其抑制Akt蛋白激酶的活性。该发明进一步涉及含有本发明化合物的化疗组合物，以及包括给予本发明化合物的方法来治疗癌症。
• [EN] AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA<br/>[FR] COMPOSÉS DE NAPHTOQUINONE D'AZIRIDINYLE ET D'AMINO DIMÈRE ET LEUR UTILISATION POUR LA LEUCÉMIE MYÉLOÏDE AIGUË
  申请人：UNIV MARYLAND

  公开号：WO2018067842A1

  公开（公告）日：2018-04-12

  The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nanomolar inhibition of cell survival in AML cells. Preferred compounds contained an aziridine or a secondary amino alcohol pharmacophore.

  这项发明涉及具有抗白血病活性的新氨基二聚萘醌化合物。与先前可获得的二聚萘醌化合物相比，本发明的化合物表现出增加的水溶性，并且对AML细胞中的细胞存活具有强效的纳摩尔级抑制作用。优选的化合物包含一个环氮乙烷或次级氨基醇药效团。
• [EN] BIS TRIDENTATE W3O2 CLUSTERS FOR X-RAY IMAGING<br/>[FR] AGRÉGATS DE LIGANDS TRIDENTÉS BIS DE W3O2 POUR L'IMAGERIE PAR RAYONS X
  申请人：BAYER IP GMBH

  公开号：WO2013000970A1

  公开（公告）日：2013-01-03

  The present invention describes a new class of highly stable W3O2 Clusters, a method for their preparation, their use as X-ray contrast agents and the intermediates tri- or tetracarboxylic acids as desired tridentate ligand resources.

  本发明描述了一种新型高稳定性的W3O2团簇，以及它们的制备方法，它们作为X射线造影剂的用途，以及作为三齿或四齿羧酸中间体的所需三齿配体资源。